Kiora Pharmaceuticals (KPRX) director awarded 25,000 stock options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Kiora Pharmaceuticals director Lisa Walters-Hoffert received a grant of stock options as part of her compensation. She was awarded 25,000 options to buy Kiora common stock at an exercise price of $2.63 per share under the company’s 2024 Equity Incentive Plan.
The options were granted at no cost and relate to 25,000 underlying shares of common stock. They will become fully exercisable on June 10, 2027 and will expire on June 10, 2036 if not exercised. After this grant, she holds 25,000 options directly, and the filing reports no open-market purchases or sales.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Walters-Hoffert Lisa
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 25,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy) — 25,000 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Option grant size: 25,000 options
Exercise price: $2.63 per share
Underlying shares: 25,000 shares
+3 more
6 metrics
Option grant size
25,000 options
Grant to director on June 10, 2026
Exercise price
$2.63 per share
Strike price for granted options
Underlying shares
25,000 shares
Common stock underlying the options
Vesting date
June 10, 2027
Date options become fully exercisable
Expiration date
June 10, 2036
Option term under 2024 Equity Incentive Plan
Options held after grant
25,000 options
Total derivative holdings following transaction
Key Terms
Stock Option, Equity Incentive Plan, exercise price, Common Stock
4 terms
Stock Option financial
"The reporting person received an Option to purchase Common Stock"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
Equity Incentive Plan financial
"pursuant to the Issuer's 2024 Equity Incentive Plan"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
exercise price financial
"conversion_or_exercise_price": "2.6300""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Common Stock financial
"Option to purchase Common Stock from the Issuer"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
FAQ
What did Kiora Pharmaceuticals (KPRX) disclose in this Form 4 filing?
Kiora Pharmaceuticals reported a stock option grant to director Lisa Walters-Hoffert. She received 25,000 options under the 2024 Equity Incentive Plan, giving her the right to buy common shares at a fixed $2.63 exercise price if she chooses to exercise later.
How many KPRX stock options were granted to director Lisa Walters-Hoffert?
Lisa Walters-Hoffert was granted 25,000 stock options to purchase Kiora common stock. Each option corresponds to one share, providing potential future ownership of 25,000 shares if exercised according to the plan’s terms and timing requirements.
What is the exercise price of the new Kiora Pharmaceuticals (KPRX) stock options?
The exercise price is $2.63 per share for the 25,000 options granted to Lisa Walters-Hoffert. This price is the fixed cost per share she must pay if she decides to exercise the options within the specified exercise period.
When do the KPRX options granted to Lisa Walters-Hoffert become exercisable?
The options become fully exercisable on June 10, 2027. Before that date, she cannot exercise them. Once vested, she may choose to buy common shares at the $2.63 exercise price any time before the option expiration date.
When do the newly granted Kiora Pharmaceuticals (KPRX) options expire?
The options expire on June 10, 2036 if they are not exercised. After that expiration date, Walters-Hoffert would lose the right to purchase Kiora common shares under this specific 25,000-option grant.